Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 3

Conditions

Pituitary Diseases 3Pituitary ACTH Hypersecretion 3Cushing Syndrome 3ACTH Syndrome, Ectopic 3Hirsutism 2Choristoma 2Adrenal Cortex Neoplasms 2

Interventions

Cisplatin 187Carboplatin 182Paclitaxel 177Docetaxel 145Cyclophosphamide 129Dexamethasone 117pembrolizumab 106Doxorubicin 103Bevacizumab 103Gemcitabine 102Rituximab 96Prednisone 87Fluorouracil 86Pemetrexed 82Radiotherapy 77Vincristine 71Etoposide 71Capecitabine 69Nivolumab 68Trastuzumab 67Leucovorin 64Cytarabine 57Methotrexate 52Oxaliplatin 49atezolizumab 48Lenalidomide 43Ipilimumab 40Filgrastim 40Bortezomib 39Sorafenib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Has results × Corlux × Clear all
NCT00936741 2014-04-02

An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

Corcept Therapeutics

Phase 3 Completed
30 enrolled 8 charts
Endocrine

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Choristoma, Cushing Syndrome, Hirsutism, Pituitary Diseases, Pituitary ACTH Hypersecretion

NCT01371565 2014-03-18

Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome

Corcept Therapeutics

Phase 3 Completed
4 enrolled 7 charts
Endocrine

ACTH Syndrome, Ectopic, Cushing Syndrome, Pituitary Diseases, Pituitary ACTH Hypersecretion

NCT00569582 2013-08-22

SEISMIC

Corcept Therapeutics

Phase 3 Completed
50 enrolled 8 charts
Endocrine

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Choristoma, Cushing Syndrome, Hirsutism, Pituitary Diseases, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡